Literature DB >> 18798555

Identification of an invasion and tumor-suppressing gene, Endoglin (ENG), silenced by both epigenetic inactivation and allelic loss in esophageal squamous cell carcinoma.

Victor Chun Lam Wong1, Pui Ling Chan, Carmelo Bernabeu, Simon Law, Li Dong Wang, Ji-Lin Li, Sai Wah Tsao, Gopesh Srivastava, Maria Li Lung.   

Abstract

Endoglin (ENG) has been identified as a candidate tumor-suppressor gene in esophageal squamous cell carcinoma (ESCC). Earlier microcell-mediated chromosome transfer (MMCT) studies of chromosome 9 in ESCC narrowed down a tumor-suppressive critical region to 9q33-34. ENG maps to 9q34-qter and encodes a transformation growth factor beta (TGFbeta) superfamily auxiliary receptor. This study aims to identify the potential role for ENG in ESCC development. Significant downregulation of ENG was detected at frequencies of 87.5% in 16 ESCC cell lines, 39.1% directly in 23 ESCC tumor specimens from Hong Kong, and 33.4% in 18 ESCC tumor specimens from the high-risk ESCC region of Henan, China. By methylation-specific PCR, methylated sequences were detected in an ESCC cell line panel and in clinical specimens. Following demethylation treatment in 9 ESCC cell lines, ENG expression was obviously restored. Loss of heterozygosity (LOH) in a 4.7 Mb region on 9q32-q34, where ENG maps, was observed directly in ESCC tumor tissues. Both epigenetic methylation and allelic loss appear to contribute to ENG downregulation in tumor cells. In vitro and in vivo functional studies such as colony formation, Matrigel culture, invasion and tumorigenicity assays were performed. Colony formation efficiency was significantly reduced by overexpression of ENG. In addition, significantly smaller colonies of ENG stable transfectants were formed in Matrigel culture. Significant suppression of invasion efficiency and tumorigenicity were also observed, when comparing the ENG stable transfectants with the vector-alone transfectants. This study provides evidence supporting ENG, as a cell invasion and tumor-suppressing gene in ESCC. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18798555     DOI: 10.1002/ijc.23882

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Endoglin suppresses human prostate cancer metastasis.

Authors:  Minalini Lakshman; Xiaoke Huang; Vijayalakshmi Ananthanarayanan; Borko Jovanovic; Yueqin Liu; Clarissa S Craft; Diana Romero; Calvin P H Vary; Raymond C Bergan
Journal:  Clin Exp Metastasis       Date:  2010-10-28       Impact factor: 5.150

2.  Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma.

Authors:  Pilar Puerto-Camacho; Ana Teresa Amaral; Salah-Eddine Lamhamedi-Cherradi; Joseph A Ludwig; Enrique de Álava; Brian A Menegaz; Helena Castillo-Ecija; José Luis Ordóñez; Saioa Domínguez; Carmen Jordan-Perez; Juan Diaz-Martin; Laura Romero-Pérez; Maria Lopez-Alvarez; Gema Civantos-Jubera; María José Robles-Frías; Michele Biscuola; Cristina Ferrer; Jaume Mora; Branko Cuglievan; Keri Schadler; Oliver Seifert; Roland Kontermann; Klaus Pfizenmaier; Laureano Simón; Myriam Fabre; Ángel M Carcaboso
Journal:  Clin Cancer Res       Date:  2018-11-12       Impact factor: 12.531

Review 3.  Review of the alterations in DNA methylation in esophageal squamous cell carcinoma.

Authors:  Yoshifumi Baba; Masayuki Watanabe; Hideo Baba
Journal:  Surg Today       Date:  2013-01-05       Impact factor: 2.549

4.  Immunohistochemical expression of endoglin offers a reliable estimation of bone marrow neoangiogenesis in multiple myeloma.

Authors:  Michael G Alexandrakis; Ioannis K Neonakis; Constantina A Pappa; Ioannis Konsolas; Maria Kokonozaki; Rodanthi Vyzoukaki; Stella Soundoulounaki; Athina Xekalou; Katerina Sfiridaki; George Tsirakis
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-13       Impact factor: 4.553

5.  Abrogated expression of DEC1 during oesophageal squamous cell carcinoma progression is age- and family history-related and significantly associated with lymph node metastasis.

Authors:  V C L Wong; J M Y Ko; R Z Qi; P J Li; L D Wang; J-L Li; Y P Chan; K W Chan; E J Stanbridge; M L Lung
Journal:  Br J Cancer       Date:  2011-02-15       Impact factor: 7.640

6.  Endoglin promoter hypermethylation identifies a field defect in human primary esophageal cancer.

Authors:  Zhe Jin; Zhenfu Zhao; Yulan Cheng; Ming Dong; Xiaojing Zhang; Liang Wang; Xinmin Fan; Xianling Feng; Yuriko Mori; Stephen J Meltzer
Journal:  Cancer       Date:  2013-07-24       Impact factor: 6.860

7.  Endoglin Is Essential for the Maintenance of Self-Renewal and Chemoresistance in Renal Cancer Stem Cells.

Authors:  Junhui Hu; Wei Guan; Peijun Liu; Jin Dai; Kun Tang; Haibing Xiao; Yuan Qian; Allison C Sharrow; Zhangqun Ye; Lily Wu; Hua Xu
Journal:  Stem Cell Reports       Date:  2017-08-08       Impact factor: 7.765

Review 8.  TGF-β superfamily co-receptors in cancer.

Authors:  John B Pawlak; Gerard C Blobe
Journal:  Dev Dyn       Date:  2021-04-09       Impact factor: 3.780

9.  Identification of Endoglin as an epigenetically regulated tumour-suppressor gene in lung cancer.

Authors:  K O'Leary; A Shia; F Cavicchioli; V Haley; A Comino; M Merlano; F Mauri; K Walter; M Lackner; M B Wischnewsky; T Crook; C Lo Nigro; P Schmid
Journal:  Br J Cancer       Date:  2015-09-01       Impact factor: 7.640

Review 10.  Promoter methylation of tumor suppressor genes in esophageal squamous cell carcinoma.

Authors:  Ji-Sheng Li; Jian-Ming Ying; Xiu-Wen Wang; Zhao-Hui Wang; Qian Tao; Li-Li Li
Journal:  Chin J Cancer       Date:  2012-05-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.